Building a quality-of-life questionnaire for people with metastatic breast cancer
Develops a questionnaire on quality of life in women with metastatic breast cancer.
Plain-language title generated from the registry record
Registry title: EORTC Metastatic Breast Cancer Module Development
Key facts
- Where
- Mumbai, IndiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with breast cancer that has spread to other parts of the body. They will be interviewed to help build a quality-of-life questionnaire.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Metastatic breast cancer (breast cancer that has spread to another part of the body), including cancer that was already spread at first diagnosis. People with brain metastases can join if they have no major cognitive impairment.
- Earlier treatment
- Must have had treatment for metastatic breast cancer (patients under observation) or be having it now. This includes chemotherapy, hormone therapy, targeted drugs, immune therapy and radiotherapy.
Main reasons for not taking part
- Early stage breast cancer
- Any psychiatric condition or cognitive impairment that would make interviews hard, as judged by the treating physician
- Took part in Phase I before
Read by machine on 9 November 2026.
Where in India
- Tata Memorial HospitalMumbai, IndiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Leeds
- Trial code
- NCT07806266
- Record updated
- 8 September 2026
- Original description
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of metastatic breast cancer (MBC) patients. There is currently an urgent and unmet need for specific tools to aid in the evaluation of HRQOL in MBC and this project aims to address these needs by developing a comprehensive EORTC questionnaire for assessing the HRQOL of this group. The new module will be used in conjunction with EORTC QLQ-C30 and will provide better measurement of the quality of life issues experienced by women with MBC. Interviews will be conducted with patients from several centres across Europe, guiding the development process in a patient centred way.Read full original descriptionShow less
The European Organisation for Research and Treatment of Cancer: Module Development for Metastatic Breast Cancer (Phase I-IIIa/b)
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of metastatic breast cancer (MBC) patients. There is currently an urgent and unmet need for specific tools to aid in the evaluation of HRQOL in MBC and this project aims to address these needs by developing a comprehensive EORTC questionnaire for assessing the HRQOL of this group. The new module will be used in conjunction with EORTC QLQ-C30 and will provide better measurement of the quality of life issues experienced by women with MBC. Interviews will be conducted with patients from several centres across Europe, guiding the development process in a patient centred way.
Inclusion: Adult females aged 18 years or over; Have a diagnosis of MBC (Breast cancer that has spread to another part of the body), including de novo MBC patients. Patients with brain metastases will be included, providing there is no associated major cognitive impairment; Have received (patients under observation) or currently receiving treatment for MBC, including chemotherapy, hormone therapy, targeted agents (anti-HER2, CDK4/6 inhibitors, mTOR/PIK3CA inhibitors, PARP inhibitors, immune therapy), radiotherapy and combinations; Conversant in the language of questionnaire administration; Have the capacity to give informed consent.
Exclusion: Patients previously involved in Phase I; Patients diagnosed with early stage breast cancer; Patients with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper participation in interviews.